First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program
June 04, 2019 06:30 ET
|
Novan, Inc.
Phase 3 pivotal program commences and underwayInvestigative sites now activated and enrollment activities actionedAnticipated patient demand managed with a highly disciplined approach to trial...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 07, 2019 16:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
Novan Completes Funding Transaction with Ligand Pharmaceuticals
May 06, 2019 09:00 ET
|
Novan, Inc.
Novan to immediately receive $12 million of non-dilutive capitalLigand to receive milestones and tiered royalty for North America SB206 molluscum indicationPhase 3 molluscum trial to begin recruitment...
Novan Secures Up to $35 Million in Non-Dilutive Funding
April 29, 2019 16:15 ET
|
Novan, Inc.
$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line resultsPipeline...
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
March 11, 2019 08:00 ET
|
Novan, Inc.
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
Novan Provides Business Update
January 30, 2019 16:15 ET
|
Novan, Inc.
End-of-Phase 2 meeting with FDA for molluscum granted and scheduled for early MarchActive business development discussions ongoing around certain late-stage assets and broader dermatology platformDr....
Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
December 10, 2018 07:30 ET
|
Novan, Inc.
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05)Statistically significant reductions in molluscum lesions as early as Week...
Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
November 14, 2018 06:30 ET
|
Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
October 01, 2018 08:05 ET
|
Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...